Core Insights - Bioventus Inc. will participate in the Morgan Stanley Global Healthcare Conference on September 10, 2025, with CFO Mark Singleton speaking [1] - A live webcast of the presentation will be available on the company's website, with a replay option following the event [2] Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products that facilitate quick and safe healing [3] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]

Core Insights - Bioventus Inc. is a global leader in innovations for active healing and will have its President and CEO, Rob Claypoole, participate in a fireside chat at the Canaccord Genuity Global Growth Conference on August 12, 2025 [1] - A live webcast of the presentation will be available on the company's website, along with a replay option after the event [2] Company Overview - Bioventus delivers clinically proven and cost-effective products aimed at helping individuals heal quickly and safely, with a mission to assist patients in resuming active lives [3] - The company's offerings include Pain Treatments, Restorative Therapies, and Surgical Solutions, all built on high quality standards and evidence-based medicine [3] - Bioventus is recognized as a trusted partner for physicians globally, emphasizing strong ethical behavior in its operations [3]

Core Viewpoint - Bioventus Inc. has secured a $400 million Senior Secured Credit Agreement, which includes a $300 million term loan and a $100 million revolving credit facility, aimed at enhancing liquidity and financial flexibility [1][2][3]. Group 1: Credit Agreement Details - The new Credit Agreement increases the revolving credit facility from $40 million to $100 million compared to the previous 2019 Credit Agreement [2]. - The interest margin has been reduced by 75 basis points, resulting in over $2 million in annual interest expense savings [2]. - The annual amortization on the term loan has been lowered from 10% to 5% for the duration of the loan [2]. Group 2: Financial Impact and Use of Proceeds - The proceeds from the Credit Agreement were utilized to repay the outstanding loan balance of $333 million under the 2019 Credit Agreement [3]. - The repayment was accomplished using $30 million drawn from the new revolving credit facility, $3 million in cash from the balance sheet, and the new $300 million term loan [3]. Group 3: Company Overview - Bioventus is recognized for delivering clinically proven, cost-effective products that facilitate quick and safe healing, with a mission to help patients resume active lives [4]. - The company focuses on innovations for active healing, including pain treatments, restorative therapies, and surgical solutions [4].

Core Insights - Bioventus Inc. will report its financial results for Q2 of fiscal year 2025 on August 6, 2025, before market opening [1] - A conference call will be held at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update [1] Company Overview - Bioventus is a global leader in innovations for active healing, delivering clinically proven and cost-effective products that aid in quick and safe healing [3] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]

Core Viewpoint - Bioventus Inc. will report its financial results for Q1 of fiscal year 2025 on May 6, 2025, before market opening, followed by a conference call for discussion [1] Group 1: Financial Reporting - The financial results for the first quarter of fiscal year 2025 will be announced before the market opens on May 6, 2025 [1] - A conference call will be held at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update [1] Group 2: Conference Call Participation - Participants can join the conference call by dialing 1-833-636-0497 and referencing the Bioventus Inc. Conference Call [2] - A live webcast of the call will be available on the Company's Investor Relations website, with an archive for replay until May 5, 2026 [2] Group 3: Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products for quick and safe healing [3] - The company's mission focuses on helping patients resume active lives through offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]